Ticker Details
Cytokinetics, Incorporated Cytokinetics Inc is a biopharmaceutical company. It is engaged in the discovery and development of novel small molecule therapeutics that modulate muscle function for the potential treatment of serious diseases and medical conditions.
IPO Date:	May 1, 2004
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$7.75B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.41 | 2.80%
Avg Daily Range (30 D):	$1.34 | 2.13%
Avg Daily Range (90 D):	$1.28 | 2.06%

Institutional Daily Volume
Avg Daily Volume:	.51M
Avg Daily Volume (30 D):	1.41M
Avg Daily Volume (90 D):	1.57M

Trade Size
Avg Trade Size (Sh.):	88
Avg Trade Size (Sh.) (30 D):	59
Avg Trade Size (Sh.) (90 D):	60

Institutional Trades
Total Institutional Trades:	8,046
Avg Institutional Trade:	$3.34M
Avg Institutional Trade (30 D):	$4.45M
Avg Institutional Trade (90 D):	$4.12M
Avg Institutional Trade Volume:	.08M
Avg Institutional Trades (Per Day):	4

Market Closing Trades
Avg Closing Trade:	$7.12M
Avg Closing Trade (30 D):	$15.15M
Avg Closing Trade (90 D):	$13.64M
Avg Closing Volume:	176.58K

News

Jan 20, 2026 @ 9:00 PM Cytokinetics Announces Inducement Grants Under Nas... Source: Na

Jan 5, 2026 @ 9:00 PM Cytokinetics to Present at the 44th Annual J.P. Mo... Source: Na

Jan 5, 2026 @ 12:00 PM Tango Therapeutics Appoints Sung Lee to Board of D... Source: Na

Dec 30, 2025 @ 2:57 PM Notice to Long-Term Shareholders of Cytokinetics, ... Source: Grabar Law Office

Dec 19, 2025 @ 9:00 PM Cytokinetics Announces FDA Approval of MYQORZOââ€... Source: Cytokinetics, Incorporated

Financials
	TTM	Q3 2025	Q2 2025
Basic EPS		$-2.55	$-1.12
Diluted EPS		$-2.55	$-1.12
Revenue		$1.94M	$66.77M
Gross Profit
Net Income / Loss		$-306.18M	$-134.37M
Operating Income / Loss		$-166.76M	$-111.51M
Cost of Revenue
Net Cash Flow		$152.03M	$2.5M
PE Ratio

Splits
Jun 25, 2013	1:6